Country: United Kingdom
Language: English
Source: VMD (Veterinary Medicines Directorate)
Canine parvovirus
Merial Animal Health Limited
QI07AD01
Canine parvovirus
Suspension for injection
POM-V - Prescription Only Medicine – Veterinarian
Dogs
Live Viral Vaccine
Expired
2005-10-28
Revised: May 2012 AN: 02062/2012 Page 1 of 4 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT EURICAN P 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each 1 ml dose of vaccine contains Freeze-dried pellet: Attenuated canine parvovirus ……………………………………….. 10 4.9 CCID 50 Excipients qs 1 dose CCID 50 = 50% cell culture infective dose. For full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Lyophilisate for suspension 4. CLINICAL PARTICULARS 4.1 TARGET SPECIES Dogs and puppies from 8 weeks of age. 4.2 INDICATIONS FOR USE SPECIFYING THE TARGET SPECIES Active immunisation of dogs from 8 weeks of age to prevent clinical signs and to reduce mortality and viral excretion caused by canine parvovirosis infection. Onset of immunity : 7 days after primary vaccination. Duration of immunity: 2 years. 4.3 CONTRA-INDICATIONS None. 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES None Revised: May 2012 AN: 02062/2012 Page 2 of 4 4.5 SPECIAL PRECAUTIONS FOR USE, INCLUDING SPECIAL PRECAUTIONS TO BE TAKEN BY THE PERSON ADMINISTERING THE MEDICINAL PRODUCT TO ANIMALS i. Special precautions for use in animals The CPV vaccine strain of EURICAN P may be shed from vaccinated animals for a number of days following vaccination. However, due to the absence of pathogenicity of the strain, it is not necessary to keep vaccinated animals separated from non– vaccinated animals. ii. Special precautions to be taken by the person administering the medicinal product to animals In case of accidental self-injection, seek medical advice immediately and show this package insert or the label to the physician. 4.6 ADVERSE REACTIONS (FREQUENCY AND SERIOUSNESS) In rare cases, slight and transient pain may be apparent at the time of injection, which regresses within 2 hours. In exceptional circumstances a hypersensitivity reaction may occur which may require appropriate symptomatic treatment. 4.7 USE DURING PREGNANCY, LACTATION OR LAY Can be used during pregnancy. In the absence of data fro Read the complete document